Kiniksa Pharmaceuticals, Ltd.

NasdaqGS:KNSA Stock Report

Market Cap: US$1.4b

Kiniksa Pharmaceuticals Past Earnings Performance

Past criteria checks 2/6

Kiniksa Pharmaceuticals has been growing earnings at an average annual rate of 42.3%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 77% per year. Kiniksa Pharmaceuticals's return on equity is 3.2%, and it has net margins of 5.2%.

Key information

42.3%

Earnings growth rate

47.7%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate77.0%
Return on equity3.2%
Net Margin5.2%
Last Earnings Update31 Dec 2023

Recent past performance updates

Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings

Nov 10
Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings

Recent updates

Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates

Mar 01
Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates

We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn

Feb 28
We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn

The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet

Dec 18
The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet

We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow

Nov 10
We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow

Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel

Apr 18
Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel

Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings

Nov 10
Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings

Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%

Aug 04
Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%

Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance

Aug 03

Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results

May 05
Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results

We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Mar 18
We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel

Nov 25

Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?

Nov 04
Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?

Kiniksa: Unexciting, Slow Growth Stock

Aug 13

We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Jul 31
We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Kiniksa outlines development path for mavrilimumab after FDA feedback

Jun 08

Kiniksa: A Look At Mavrilimumab

May 03

Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation

Apr 17
Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation

What Kind Of Investors Own Most Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)?

Jan 02
What Kind Of Investors Own Most Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)?

Kiniksa's antibody treatment shows clinical benefit in late-stage COVID-19 study

Dec 22

Dosing underway in Kiniksa Pharma's lumpy skin disease study with vixarelimab

Dec 15

Kiniksa Pharma's KPL-404 shows encouraging action in early-stage study

Nov 30

Kiniksa's vixarelimab nabs accelerated review in U.S. for a skin disorder

Nov 16

Revenue & Expenses Breakdown
Beta

How Kiniksa Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:KNSA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 232701412976
30 Sep 23249-712070
30 Jun 2328123111070
31 Mar 2323619610560
31 Dec 222201839865
30 Sep 221771439379
30 Jun 2290-1129081
31 Mar 2271-1348891
31 Dec 2139-1588699
30 Sep 2120-17579109
30 Jun 218-18970121
31 Mar 210-18457120
31 Dec 200-16145112
30 Sep 200-1403899
30 Jun 200-1233589
31 Mar 200-1223597
31 Dec 190-16235135
30 Sep 190-17335147
30 Jun 190-17031146
31 Mar 190-15327133
31 Dec 180-1032287
30 Sep 180-931680
30 Jun 180-851374
31 Mar 180-761165
31 Dec 170-65956

Quality Earnings: KNSA has high quality earnings.

Growing Profit Margin: KNSA's current net profit margins (5.2%) are lower than last year (83.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: KNSA has become profitable over the past 5 years, growing earnings by 42.3% per year.

Accelerating Growth: KNSA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: KNSA had negative earnings growth (-92.3%) over the past year, making it difficult to compare to the Biotechs industry average (-8.9%).


Return on Equity

High ROE: KNSA's Return on Equity (3.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.